<div class="content-intro"><p></p> <div data-ogsc="black"><span data-ogsc="" data-ogsb="yellow"><strong data-ogsc="" data-olk-copy-source="MessageBody">.
Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome.
We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs.
At Acadia, we’re here to be their difference.
</span></div></div><p><span style="text-decoration: underline;"><strong>Position Summary</strong></span></p> <p><br>The Senior Medical Science Liaison (Sr MSL) for France plays a pivotal role in advancing our mission in rare pediatric/adult neurodevelopmental diseases, with a core focus on Rett syndrome.
This field-based role serves as a trusted scientific partner to healthcare professionals, researchers, advocacy groups, and decision makers across France.
The Sr MSL drives scientific exchange, supports evidence generation, and helps ensure patients, caregivers, and clinicians have access to high-quality scientific and medical information about Acadia’s therapeutic innovations.
</p> <p><span style="text-decoration: underline;"><strong>Scope</strong></span></p> <ul> <li><strong>Scientific Engagement & Stakeholder</strong> <strong>Partnership –</strong> Serve as Acadia’s field-based scientific expert, building trusted relationships with healthcare professionals, key opinion leaders, centers of excellence, and patient advocacy organizations ac.